Latest Topamax news
Amitriptyline, Topiramate Don’t Cut Pediatric Migraine vs Placebo
posted October 27th
by modernClinician Editorial Team
by modernClinician Editorial Team
For children and adolescents with migraine, amitriptyline and topiramate do not reduce headache frequency or headache-related disability more than placebo, according to a study published online Oct. 27 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the Child Neurology Society, held from Oct. 26 to 29 in Vancouver, Canada.
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes
Botox Helpful in Alleviating Chronic Migraine in Pediatric Patients
Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV
28 Percent of U.S. Adults With HTN Eligible for Treatment Under New Guidelines
Vascular Burden in Midlife Linked to Increased Risk for Dementia, Death
Hypoglossal Nerve Stimulation May Offer Long-Term Cardiovascular Benefits in OSA
Timing of JAK Initiation, Shingles Vaccine Administration Can Affect Outcomes in RA
2018 to 2024 Saw Rise in Insurance Denials for Brand-Name Drugs